Demars Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$333K Sell
2,604
-209
-7% -$26.1K 0.11% 83
2025
Q4
$343K Hold
2,813
0.11% 73
2025
Q3
$282K Sell
2,813
-162
-5% -$14.6K 0.1% 77
2025
Q2
$247K Sell
2,975
-3,110,373
-100% -$248M 0.09% 77
2025
Q1
$38.4M Buy
3,113,348
+874
+0% +$78.1K 1.1% 16
2024
Q4
$34.6M Buy
+3,112,474
New +$302M 1.11% 16

Other funds holding XBI

Demars Financial Group's XBI Position: Q1 2026 in Review

Demars Financial Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.4% in Q1 2026, selling an estimated $26.1K and leaving 2,604 shares worth $333K. The position accounts for 0.11% of the portfolio, ranked #83.

Demars Financial Group first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. The position peaked at $38.4M in Q1 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Demars Financial Group held 2,604 shares of State Street SPDR S&P Biotech ETF worth $333K as of Q1 2026.
  • Demars Financial Group sold 209 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $26.1K.
  • State Street SPDR S&P Biotech ETF made up 0.11% of Demars Financial Group's portfolio in Q1 2026, its #83 holding.
  • Demars Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
  • Demars Financial Group's State Street SPDR S&P Biotech ETF position peaked at $38.4M in Q1 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Demars Financial Group's 13F filing for Q1 2026, filed 30 Apr 2026.